Skip to content

Study · Non-randomized trial · n = 17 · 2004

6 results

Antidiuretic action of oxytocin is associated with increased urinary excretion of aquaporin-2.

Joo KW, Jeon US, Kim GH, Park J, Oh YK, Kim YS, Ahn C, Kim S, Kim SY, Lee JS, Han JS

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association27 Jul 2004Cited by 24 (Europe PMC)

PMID15280526 (opens in a new tab)DOI10.1093/ndt/gfh413 (opens in a new tab)PepBankPUB-15280526
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers and patients with central diabetes insipidus, intravenous oxytocin decreased urine volume.

    In plain wordsIn healthy people and people with central diabetes insipidus, oxytocin infusion lowered urine volume.

    Peptide
    Oxytocin
    Outcome
    DecreaseUrine volume
    Study

    n = 17

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Urine volume and free water clearance were decreased, and urine osmolality was increased by the administration of oxytocin or dDAVP in the normal volunteers and CDI patients.
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers and patients with central diabetes insipidus, intravenous oxytocin decreased free water clearance.

    In plain wordsIn healthy people and people with central diabetes insipidus, oxytocin infusion lowered free water clearance.

    Peptide
    Oxytocin
    Outcome
    DecreaseFree water clearance
    Study

    n = 17

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Urine volume and free water clearance were decreased, and urine osmolality was increased by the administration of oxytocin or dDAVP in the normal volunteers and CDI patients.
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy volunteers and patients with central diabetes insipidus, intravenous oxytocin increased urine osmolality.

    In plain wordsIn healthy people and people with central diabetes insipidus, oxytocin infusion made urine more concentrated.

    Peptide
    Oxytocin
    Outcome
    IncreaseUrine osmolality
    Study

    n = 17

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    Urine volume and free water clearance were decreased, and urine osmolality was increased by the administration of oxytocin or dDAVP in the normal volunteers and CDI patients.
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, intravenous oxytocin increased urinary aquaporin-2 excretion.

    In plain wordsIn healthy people, oxytocin infusion raised the amount of aquaporin-2 in urine.

    Peptide
    Oxytocin
    Outcome
    IncreaseUrinary AQP2 excretion, normal volunteers
    Study

    n = 10

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Measurements

    Urinary AQP2 before oxytocin
    34 DU/2 h
    normal volunteers
    Urinary AQP2 after oxytocin
    326 DU/2 h
    normal volunteers

    Source sentences

    Summary
    Urinary AQP2 excretion was increased by oxytocin infusion in the normal volunteers (from 34+/-12 to 326+/-120 densitometry unit (DU)/2 h)
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with central diabetes insipidus, intravenous oxytocin increased urinary aquaporin-2 excretion.

    In plain wordsIn people with central diabetes insipidus, oxytocin infusion raised the amount of aquaporin-2 in urine.

    Peptide
    Oxytocin
    Outcome
    IncreaseUrinary AQP2 excretion, central diabetes insipidus
    Study

    n = 7

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Measurements

    Urinary AQP2 before oxytocin
    8 DU/2 h
    CDI group
    Urinary AQP2 after oxytocin
    227 DU/2 h
    CDI group

    Source sentences

    Summary
    in the CDI group (from 8+/-2 to 227+/-92 DU/2 h) (P<0.05)
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with nephrogenic diabetes insipidus, intravenous oxytocin did not increase urinary aquaporin-2 excretion.

    In plain wordsIn people with nephrogenic diabetes insipidus, oxytocin infusion did not raise aquaporin-2 in urine.

    Peptide
    Oxytocin
    Outcome
    No significant changeUrinary AQP2 excretion, nephrogenic diabetes insipidus
    Study

    n = 3

    Comparator
    Before oxytocin administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 mU/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    but not in the NDI group. dDAVP also had a similar but more potent effect on the urinary excretion of AQP2 in the normal and CDI groups.
    2 context sentences
    Summary · context
    Oxytocin was administered intravenously at a rate of 20 mU/min in 10 healthy volunteers, seven patients with central diabetes insipidus (CDI) and three patients with nephrogenic diabetes insipidus (NDI).
    Summary · context
    Two-hour urine was collected before and after the administration of oxytocin and dDAVP, and urinary AQP2 was measured semi-quantitatively by western analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.